Register now atPeruvian Society of Medical Oncology

spom@spomedica.org

THEWESTINLIMA HOTELCalle Las Begonias450, San Isidro

JULY12-13

LIMAPERU

PRO

GRA

MB

est

of

ASC

O 2

019

2

Foto: Shutterstock

LIMAPERU

PRO

GRA

MB

est

of

ASC

O 2

019

3

PRESIDENT

PRES

ENTA

TIO

N

Estimados colegas:

Best

of

ASC

O 2

019

3

La Sociedad Peruana de Oncología Médica, orientada a la educación médica continua del Oncólogo peruano pone al alcance de todos sus asociados los últimos avances en el conocimiento médico científico de la oncología clínica expuestos en la Edición 55ta. de la Reunión de ASCO, que este año tuvo como tema central “Cuidar de cada paciente, aprender de cada paciente”.

Los avances en inmunoterapia, terapia target y el diagnóstico molecular del Cáncer ofrecen cada vez una mayor oportunidad de control y tratamiento de esta enfermedad. Sin embargo, no basta la investigación bási-ca y clínica para lograr un mejor control del cáncer sino encontramos la forma de que más pacientes tengan un acceso oportuno a estos avances en diagnóstico y tratamien-to innovadores.

La presente reunión, nos sirva para mejorar nuestras competencias de trabajo en equipo multidisciplinario, practica de la oncología basada en la evidencia y atención centrada en el paciente.

Bienvenidos a todos Ustedes Colegas a este importante evento The Best of Asco 2019.

LUIS VERA VALDIVIA MD

PRO

GRA

MB

est

of

ASC

O 2

019

4

Luis Alberto Vera Valdivia MDPresident

Silvia Patricia Neciosup Delgado MDVice President

María Liliana Vásquez Ponce MDSecretary General

Milagros Cavero Cosar MDFinances Secretary

Rodrigo Auqui Flores MDNational Coordinator

Rolig Abad Aliaga Chávez MDChairman of Scientific Affairs

Alejandro Kobashigawa Miyahira MDChairman of Internal Affairs

Hernán David Morón Escobar MDChairman Ethics Committee

PERUVIAN SOCIETY OFMEDICAL ONCOLOGY

FAC

ULT

YB

est

of

ASC

O 2

019

4

PRO

GRA

MB

est

of

ASC

O 2

019

5

SPEA

KERS

Best

of

ASC

O 2

019

5

ATILIO ROMERO MD | PERUFERNANDO HURTADO DE MENDOZA MD | PERUHENRY GÓMEZ MD | PERUHUGO FUENTES MD | PERUMIGUEL TICONA MD | PERUMÓNICA CALDERÓN MD | PERUOSCAR CARNERO MD | PERUSALLY PAREDES MD | PERUSHIRLEY QUINTANA MD | PERU

ANDREA WAHNER MD | USAKONSTANTINOS LEVENTAKOS MD | USAMINETTA LIU MD | USAROBERT MACWILLIAMS MD| USASIKANDER AILAWADHI MD | USA

PRO

GRA

MB

est

of

ASC

O 2

019

6

DAY 1 JULY 12, 2019

JULY 11, 2019

OPENING

SYMPTOMS AND SURVIVORSHIP

GENITOURINARY (PROSTATE) CANCER

MORNING PROGRAM

Sally Paredes MD - PERU

Atilio Romero MD - PERU

8:50-9:00 h

9:00-9:30 h

9:30-10:10 h

• The impact of routine ESAS use on overall survival: Results of a popu-lation-based retrospective matched cohort analysis.

• Overall survival (OS) results of a phase III randomized trial of stan-dard-of-care therapy with or with-out enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

• Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.

• Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalut-amide and Ra223 versus enzalutamide alone: An interim safety analysis.

• A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain.

• Alliance A031201: A phase III trial of en-zalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant pros-tate cancer (mCRPC).

• A randomized, double-blind, place-bo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients re-ceiving cisplatin-based chemotherapy: J-FORCE Study.

• First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen depriva-tion therapy (ADT).

SYMPOSIUM BIOTOSCANA20:00-21:00 h

PRO

GRA

M

7

Best

of

ASC

O 2

019

GENITOURINARY (NONPROSTATE) CANCER

SARCOMA

CENTRAL NERVOUS SYSTEM TUMORS

BREAK

Oscar Carnero MD - PERU

Fernando Hurtado de Mendoza MD - PERU

Mónica Calderón MD - PERU

10:10-10:50 h

11:20-11:50 h

11:50-12:20 h

10:50-11:20 h

• Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line thera-py for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

• Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolo-mide in anaplastic glioma without 1p/19q codeletion.

• Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemo-therapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.

• Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.

• EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.

• Single agent ONC201 in adult recur-rent H3 K27M-mutant glioma.

• CALGB 90601 (Alliance): Random-ized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.

• Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEI-NO) trial.

• ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

• STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.

• Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

PRO

GRA

MB

est

of

ASC

O 2

019

8

MELANOMA/SKIN CANCER

HEAD AND NECK CANCER

SYMPOSIUM - BRISTOL - MELANOMA

Hugo Fuentes MD - PERU

Miguel Ticona MD - PERU

12:20-13:00 h

15:00-15:45 h

13:10-14:50 h

• Ipilimumab versus placebo after com-plete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 random-ized trial.

• Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

• Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

• Pathological response and survival with neoadjuvant therapy in mela-noma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

• Gemcitabine and cisplatin (GP) in-duction chemotherapy (IC) plus con-current chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcino-ma (NPC): A phase 3, multicenter, randomized controlled trial.

• Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

• Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

• Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treat-ment of 1-3 melanoma brain metasta-ses (MBMs).

• TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HN-SCC).

AFTERNOON PROGRAM

PRO

GRA

MB

est

of

ASC

O 2

019

9

GYNECOLOGIC CANCER

LUNG CANCER – NON-SMALL CELL METASTATIC

SYMPOSIUM - ROCHE - PULMÓN

BREAK

Andrea Wahner-Hendrickson MD - USA

Konstantinos Leventakos MD - USA

15:45-16:30 h

17:00-17:45 h

17:45-19:45 h

16:30-17:00 h

• A randomized phase 3 trial of pacl-itaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemo-therapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncol-ogy trial.

• RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirum-ab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-posi-tive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

• Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mu-tated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

• ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.

• EWOC-1: A randomized trial to eval-uate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG- EN-GOT-GINECO study.

• Blood tumor mutational burden (bTMB) and tumor PD-L1 as predic-tive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelim-umab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

• Combination of niraparib and bev-acizumab versus niraparib alone as treatment of recurrent platinum-sen-sitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

• Phase III randomized trial compar-ing gefitinib to gefitinib with peme-trexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung can-cer (gef vs gef+C).

PRO

GRA

MB

est

of

ASC

O 2

019

10

Foto: Shutterstock

PRO

GRA

MB

est

of

ASC

O 2

019

11

DAY 2 JULY 13, 2019

SYMPOSIUM - ROCHE - MAMA

HEMATOLOGIC MALIGNANCIES- PLASMA CELL DYSCRASIA

HEMATOLOGIC MALIGNANCIES- LEUKEMIA MYELODYSPLASTIC SYNDROMES, AND ALLOTRANSPLANT

MORNING PROGRAM

Sikander Ailawadhi MD - USA

Shirley Quintana MD - PERU

8:00-9:00 h

9:00-9:45 h

9:45-10:30 h

• E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

• Effect of gilteritinib on survival in pa-tients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

• Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with re-lapsed or refractory multiple myeloma (RRMM): COLUMBA.

• ENESTop 192-week results: Treat-ment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

• Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immu-notherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.

• End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lympho-blastic leukemia (ALL).

• A phase III randomized, open label, multicenter study comparing isatux-imab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in pa-tients with relapsed/refractory multiple myeloma (RRMM).

• Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia.

BREAK10:30-11:00 h

PRO

GRA

MB

est

of

ASC

O 2

019

12

LUNG CANCER – NON-SMALL CELL LOCAL REGIONAL/SMALL CELL/THORACIC CANCERS

GASTROINTESTINAL (COLORECTAL) CANCER

Konstantinos Leventakos MD - USA

Robert McWilliams MD - USA

11:00-11:45 h

11:45-12:30 h

• Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiother-apy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).

• Prospective pooled analysis of four randomized trials investigating dura-tion of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

• Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

• NRG-GI002: A Phase II Clinical Trial Platform using Total Neoadjuvant Therapy (TNT) in Locally-advanced Rectal Cancer: First Experimental Arm Initial Results

• Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

• Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

• Neoadjuvant atezolizumab in resect-able non-small cell lung cancer (NS-CLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

• FOxTROT: an international ran-domised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

PRO

GRA

MB

est

of

ASC

O 2

019

13

AFTERNOON PROGRAM

SYMPOSIUM - MSD - PULMÓN

HEMATOLOGIC MALIGNANCIES- LYMPHOMA AN CHRONIC LYMPHOCYTIC LYMPHOMA

GASTROINTESTINAL (NONCOLORECTAL) CANCER

Sikander Ailawadhi MD - USA

Robert McWilliams MD - USA

12:40-14:30 h

15:00-15:45 h

16:15-17:00 h

• Effect of montelukast and rupatadine on rituximab infusion time, rate, severity of reactions, and cost of administration.

• Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

• Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lympho-ma Group phase III study.

• ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

• Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lympho-ma (CLL/SLL) on ibrutinib.

• Umbralisib monotherapy demon-strates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

• Pembrolizumab With or Without Chemotherapy Versus Chemotherapy in Advanced G/GEJ Adenocarcinoma: The Phase 3, KEYNOTE-062 Study

• Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progres-sion-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreat-ed patients (pts) with chronic lympho-cytic leukemia (CLL) and comorbidities.

• APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

BREAK15:45-16:15 h

PRO

GRA

MB

est

of

ASC

O 2

019

14

BREAST CANCER-LOCAL/REGIONAL/ADJUVANT: ADJUVANT THERAPY

BREAST CANCER-METASTATIC

Henry Gómez MD - PERU

Minetta Liu MD - USA

Silvia Neciosup MD

17:00-17:45 h

17:45-18:30 h

• Impact of clinical risk category on prognosis and prediction of chemo-therapy benefit in early breast cancer (EBC) by age and the 21-gene recur-rence score (RS) in TAILORx.

• SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

• Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.

• IMpassion130: updated overall sur-vival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or met-astatic triple-negative breast cancer (mTNBC).

• Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initia-tive randomized clinical trial.

• Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

• Benefit from letrozole as extended adjuvant therapy after sequential en-docrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

• Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-di-rected regimens: Findings from the multinational, randomized, phase III NALA trial.

SYMPOSIUM - JANSSEN - PRÓSTATA18:30-20:30 h

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

LIMAPERU

Foto: Shutterstock

COURTESY